Tagged with Pharma Mar

Europe The European MidPharma Performance Ranking 2019 is taken from The Novasecta European Midpharma Report 2019, which examines how European mid-cap pharma companies are surviving and thriving. With scores assigned to R&D investment, commercial revenues and business development, this is a comprehensive list of the recent performance of some of Europe’s…

Sweden The size of the Swedish pharma market is dwarfed by those of the EU5, but Sweden does host the largest market in the Nordics region, ahead of  Denmark, Finland and Norway. Made with Visme Infographic Maker   Sweden produced over EUR 7 billion worth of pharmaceuticals in 2015, a considerable…

USA 80 orphan drugs (those drugs intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions) were approved in the USA in 2017, a record year and more than double the 40 approved in 2016.   Orphan drug spending grew from 5 to 10%…

Malaysia The growth of the Malaysian pharma market between 2006 and 2016. Pharmaceutical sales grew to over USD 2 billion by 2016, thanks in large part to a burgeoning prescription medicine segment.   The import and export of pharmaeuticals in Malaysia between 2006 and 2016. In 2016, the trade balance stood…

China China has expanded to be the second largest pharmaceutical market globally with USD 137 billion in total spending in 2018, but growth has slowed from a 19% CAGR in 2008–2013 to an 8% CAGR in 2013–2018 and is expected to continue to decline to 3-6% through 2023, as the below…

Egypt The Egyptian pharma market grew at a compound annual growth rate (CAGR) of 17 percent between 2011 and 2017 to reach a total market valuation of EGP 50 billion in 2017. Low levels of healthcare insurance penetration mean that pharma sales are predominantly driven by out-of-pocket expenditure.   The top…

Europe The Top Pharma Markets in Europe for 2016 according to the latest EFPIA figures. Germany leads the way, with a market size of EUR 30.815 billion, followed by France and Italy.

Europe 125 medicines for rare diseases were approved by the EMA between 2004 and 2014, of which 71 were granted orphan drug status. This chart shows the availability of 112 of these drugs across European countries. The largest number of medicines for rare diseases were in continuous use in Germany and…

Europe European countries ranked by the levels of generics penetration within their domestic markets. Poland comes out on top by this measurement, with generic medicines making up a full 60.4% of market sales value, followed closely by Russia and Italy. At the other end of the scale, generics make up just…

UK There is much debate surrounding the potential impact on the UK’s life sciences industry of the country’s decision to leave the European Union. Here, IQVIA analysis posits ‘upside’ and ‘downside’ Brexit scenarios on pharmaceutical market sales and growth in the UK in comparison to a theoretical ‘No Brexit’ scenario. Different…